A. D. Darenskaya
Research Subjects
A. D. Darenskaya has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Bela M. Medvedeva
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
5 shared publications - Alexey A. Rumyantsev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
3 shared publications E.V. Stepanova Stepanova
2 shared publicationsMedvedeva B.M. Medvedeva
2 shared publicationsN.V. Dobrova Dobrova
2 shared publications- Аleksandra S. Tyulyandina
N. N. Blokhin National Medical Research Center of Oncology; I. M. Sechenov First Moscow State Medical University (Sechenov University)
2 shared publications
Latest Publications
- 16 December 2024
- Published by Alfmed LLC in Medical alphabet
- No. 27,p. 42-48
Disseminated spontaneous postsplenectomy splenosis mimicking disseminated malignant tumor process. Clinical observation
This article is devoted to such a benign acquired condition as postsplenectomy splenosis, which is often incorrectly interpreted as a primary malignant tumor or secondary (metastatic) tumor process. The article provides a modern definition of the concept of «splenosis», examines the main mechanisms of autotransplantation of splenic tissue, indicates the most typical localizations of splenosis foci, provides the timing of the onset of splenosis, considers possible clinical manifestations and potential complications of this condition, discusses modern approaches to diagnostics, differential diagnostics of splenosis, tactics of management and treatment of such patients in detail, and also provides own author’s clinical observation of disseminated spontaneous postsplenectomy splenosis mimicking disseminated malignant tumor process. The feature of this clinical case is the presence of hereditary microspherocytosis (congenital microspherocytic hemolytic anemia, Minkowski-Chauffard disease) in the patient, which served as the reason for splenectomy. The article is illustrated with original computed tomography and magnetic resonance imaging.
- 16 December 2024
- Published by Alfmed LLC in Medical alphabet
- No. 27,p. 42-48
Disseminated spontaneous postsplenectomy splenosis mimicking disseminated malignant tumor process. Clinical observation
This article is devoted to such a benign acquired condition as postsplenectomy splenosis, which is often incorrectly interpreted as a primary malignant tumor or secondary (metastatic) tumor process. The article provides a modern definition of the concept of «splenosis», examines the main mechanisms of autotransplantation of splenic tissue, indicates the most typical localizations of splenosis foci, provides the timing of the onset of splenosis, considers possible clinical manifestations and potential complications of this condition, discusses modern approaches to diagnostics, differential diagnostics of splenosis, tactics of management and treatment of such patients in detail, and also provides own author’s clinical observation of disseminated spontaneous postsplenectomy splenosis mimicking disseminated malignant tumor process. The feature of this clinical case is the presence of hereditary microspherocytosis (congenital microspherocytic hemolytic anemia, Minkowski-Chauffard disease) in the patient, which served as the reason for splenectomy. The article is illustrated with original computed tomography and magnetic resonance imaging.
- 8 November 2024
- Published by Bionika Media in Pharmateca
- Vol. 6_2024
Splenosis in oncological practice. A modern view of the problem (literature review)
- 8 November 2024
- Published by Bionika Media in Pharmateca
- Vol. 6_2024
Splenosis in oncological practice. A modern view of the problem (literature review)
- Open Access
- 20 September 2024
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 7 (3) , 82-86
An Accessory Spleen in the Liver Gate: a Clinical Case Report
This article is dedicated to such a congenital anomaly of human development as an accessory spleen. In our article we discuss the main causes of its occurrence, indicate the most frequent localizations, discuss the complexity of diagnosis, and demonstrate the modern possibilities of medical imaging in differential diagnosis of this pathology with other neoplasms of the abdominal cavity. Moreover, we present a clinical case of an accessory spleen located in an atypical place — in the liver gates, which is a rare finding. The article is illustrated with original computed tomography, magnetic resonance imaging, and radionuclide studies scans.
- 20 September 2024
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 7 (3) , 82-86
Open AccessAn Accessory Spleen in the Liver Gate: a Clinical Case Report
This article is dedicated to such a congenital anomaly of human development as an accessory spleen. In our article we discuss the main causes of its occurrence, indicate the most frequent localizations, discuss the complexity of diagnosis, and demonstrate the modern possibilities of medical imaging in differential diagnosis of this pathology with other neoplasms of the abdominal cavity. Moreover, we present a clinical case of an accessory spleen located in an atypical place — in the liver gates, which is a rare finding. The article is illustrated with original computed tomography, magnetic resonance imaging, and radionuclide studies scans.
- Open Access
- 12 September 2024
- Published by Publishing House ABV Press in Bone and soft tissue sarcomas, tumors of the skin
- Vol. 16 (3) , 71-80
Rare case of primary cardiac osteosarcoma
Primary cardiac osteosarcoma is an extremely rare malignant tumor, its incidence is less than 10 % of all primary cardiac sarcomas. Currently, less than 100 cases of this disease have been reported, and there is no consensus on the optimal approaches to treatment. The article presents a clinical case of primary cardiac osteosarcoma noting the effectiveness of two chemotherapy lines and describes difficulties in tumor morphology interpretation.
- 12 September 2024
- Published by Publishing House ABV Press in Bone and soft tissue sarcomas, tumors of the skin
- Vol. 16 (3) , 71-80
Open AccessRare case of primary cardiac osteosarcoma
Primary cardiac osteosarcoma is an extremely rare malignant tumor, its incidence is less than 10 % of all primary cardiac sarcomas. Currently, less than 100 cases of this disease have been reported, and there is no consensus on the optimal approaches to treatment. The article presents a clinical case of primary cardiac osteosarcoma noting the effectiveness of two chemotherapy lines and describes difficulties in tumor morphology interpretation.
- 2 September 2024
- Published by Bionika Media in Pharmateca
- Vol. 4_2024
Current state of the problem of diagnosing the accessory spleen. Literature review
- 2 September 2024
- Published by Bionika Media in Pharmateca
- Vol. 4_2024
Current state of the problem of diagnosing the accessory spleen. Literature review
- Open Access
- 21 December 2023
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 13 (3) , 49-56
Complete radiological response when using pembrolizumab in the mono mode in the 2nd-line drug therapy of MSI-h / dMMR-positive advanced endometrial cancer. A clinical case
Until recently, the prognosis of patients with advanced endometrial cancer remained disappointing despite the standard treatment methods. None of the drugs in the arsenal of oncologists-chemotherapists provided long-term disease control and long-term survival of patients who received standard platinum-containing first-line chemotherapy. It is obvious that the poor results of treatment in patients with advanced endometrial cancer required a change in treatment approaches and indicated the need to develop more effective treatment regimens. A deeper understanding of the mechanisms of carcinogenesis, the emergence of new molecular classification of endometrial cancer and division of treatment approaches depending on the tumor biological potential has led to significant breakthrough in the treatment of advanced endometrial cancer. One of the most significant achievements is discovery of the function of microsatellite instability (MSI) and disorders in the repair system of unpaired bases of deoxyribonucleic acid (MMR) as a predictor of high efficient immunotherapy – a new direction of systemic drug therapy for the advanced endometrial cancer. The paper presents a clinical case of successful treatment of MSI-h / dMMR-positive advanced endometrial cancer using pembrolizumab as a second-line therapy (in the presence of refractoriness to standard platinum-based chemotherapy of the 1st line) in a mono mode with a complete radiological response of the tumor to treatment.
- 21 December 2023
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 13 (3) , 49-56
Open AccessComplete radiological response when using pembrolizumab in the mono mode in the 2nd-line drug therapy of MSI-h / dMMR-positive advanced endometrial cancer. A clinical case
Until recently, the prognosis of patients with advanced endometrial cancer remained disappointing despite the standard treatment methods. None of the drugs in the arsenal of oncologists-chemotherapists provided long-term disease control and long-term survival of patients who received standard platinum-containing first-line chemotherapy. It is obvious that the poor results of treatment in patients with advanced endometrial cancer required a change in treatment approaches and indicated the need to develop more effective treatment regimens. A deeper understanding of the mechanisms of carcinogenesis, the emergence of new molecular classification of endometrial cancer and division of treatment approaches depending on the tumor biological potential has led to significant breakthrough in the treatment of advanced endometrial cancer. One of the most significant achievements is discovery of the function of microsatellite instability (MSI) and disorders in the repair system of unpaired bases of deoxyribonucleic acid (MMR) as a predictor of high efficient immunotherapy – a new direction of systemic drug therapy for the advanced endometrial cancer. The paper presents a clinical case of successful treatment of MSI-h / dMMR-positive advanced endometrial cancer using pembrolizumab as a second-line therapy (in the presence of refractoriness to standard platinum-based chemotherapy of the 1st line) in a mono mode with a complete radiological response of the tumor to treatment.
- Open Access
- 20 December 2023
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 19 (4) , 132-139
Combination of pembrolizumab and lenvatinib in second-line therapy for MSS/pMMR advanced endometrial cancer: literature review and a case report
Despite the existing standard treatments for endometrial cancer, the prognosis for these patients remained poor until recently. None of currently available cytostatics ensured long-term disease control and long-term survival of patients receiving standard platinum-based therapy. Poor treatment outcomes in patients with advanced endometrial cancer necessitated changes in therapeutic approaches and development of more effective treatment regimens. Better understanding of carcinogenesis mechanisms, emergence of a new molecular classification of endometrial cancer, and implementation of tailored treatment approaches based on tumor types led to a significant breakthrough in the treatment of advanced endometrial cancer. Currently, the most effective second-line therapy for endometrial cancer with high level microsatellite instability (MSI-h) or deficient mismatch repair system (dMMR) (25 % of cases), and no indications for surgery is pembrolizumab monotherapy. Most of cancers (about 75 %) are represented by microsatellite-stable and mismatch repair proficient tumors (MSS/рMMR). Patients with such tumors demonstrating disease progression after systemic therapy should receive a combinations of the immune checkpoint inhibitor pembrolizumab and the multi-targeted tyrosine kinase inhibitor lenvatinib. In this article, we review relevant literature and report a case of successful treatment of MSS/pMMR advanced endometrial cancer with a combination of pembrolizumab and lenvatinib as a second-line therapy (after disease progression in response to platinum-containing first-line chemotherapy), which ensured long-term disease control.
- 20 December 2023
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 19 (4) , 132-139
Open AccessCombination of pembrolizumab and lenvatinib in second-line therapy for MSS/pMMR advanced endometrial cancer: literature review and a case report
Despite the existing standard treatments for endometrial cancer, the prognosis for these patients remained poor until recently. None of currently available cytostatics ensured long-term disease control and long-term survival of patients receiving standard platinum-based therapy. Poor treatment outcomes in patients with advanced endometrial cancer necessitated changes in therapeutic approaches and development of more effective treatment regimens. Better understanding of carcinogenesis mechanisms, emergence of a new molecular classification of endometrial cancer, and implementation of tailored treatment approaches based on tumor types led to a significant breakthrough in the treatment of advanced endometrial cancer. Currently, the most effective second-line therapy for endometrial cancer with high level microsatellite instability (MSI-h) or deficient mismatch repair system (dMMR) (25 % of cases), and no indications for surgery is pembrolizumab monotherapy. Most of cancers (about 75 %) are represented by microsatellite-stable and mismatch repair proficient tumors (MSS/рMMR). Patients with such tumors demonstrating disease progression after systemic therapy should receive a combinations of the immune checkpoint inhibitor pembrolizumab and the multi-targeted tyrosine kinase inhibitor lenvatinib. In this article, we review relevant literature and report a case of successful treatment of MSS/pMMR advanced endometrial cancer with a combination of pembrolizumab and lenvatinib as a second-line therapy (after disease progression in response to platinum-containing first-line chemotherapy), which ensured long-term disease control.
- Open Access
- 21 June 2023
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 13 (2) , 80-98
Evolution of systemic therapy for disseminated endometrial cancer: literature review
The TC combination regimen (paclitaxel + carboplatin) is the “gold standard” first-line therapy for disseminated endometrial cancer (EC). The use of hormone therapy (HT) in the first-line setting is limited. Until recently, patients with disseminated EC had unfavorable outcomes despite the standard-of-care treatment (chemotherapy (CHT) and HT). None of the available cytostatics could improve disease control and survival in patients who have received standard platinum-based therapy. Evidently, the poor treatment outcomes of disseminated EC suggested that therapeutic approaches should be changed, and more effective treatment regimens should be developed. The treatment of disseminated EC has been revolutionized with deeper understanding of carcinogenesis, a new molecular classification of EC, and stratification of treatment approaches according to the biological potential of the tumor. The most significant advances included understanding the role of microsatellite instability (MSI) and DNA mismatch repair (MMR) deficiencies as a predictor of high efficacy of immunotherapy, a novel class of systemic therapies for disseminated EC. This review article focuses on the evolution of systemic therapy for disseminated EC. Here we discuss in detail the results of key international trials of HT, first and second lines of chemotherapy, targeted therapy, immunotherapy, and immunotherapeutic/ targeted agents for disseminated EC. Biological markers, such as MSI and PD-L1, their correlation with the response rate, and the mechanism of synergy between pembrolizumab and lenvatinib are discussed in detail.
- 21 June 2023
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 13 (2) , 80-98
Open AccessEvolution of systemic therapy for disseminated endometrial cancer: literature review
The TC combination regimen (paclitaxel + carboplatin) is the “gold standard” first-line therapy for disseminated endometrial cancer (EC). The use of hormone therapy (HT) in the first-line setting is limited. Until recently, patients with disseminated EC had unfavorable outcomes despite the standard-of-care treatment (chemotherapy (CHT) and HT). None of the available cytostatics could improve disease control and survival in patients who have received standard platinum-based therapy. Evidently, the poor treatment outcomes of disseminated EC suggested that therapeutic approaches should be changed, and more effective treatment regimens should be developed. The treatment of disseminated EC has been revolutionized with deeper understanding of carcinogenesis, a new molecular classification of EC, and stratification of treatment approaches according to the biological potential of the tumor. The most significant advances included understanding the role of microsatellite instability (MSI) and DNA mismatch repair (MMR) deficiencies as a predictor of high efficacy of immunotherapy, a novel class of systemic therapies for disseminated EC. This review article focuses on the evolution of systemic therapy for disseminated EC. Here we discuss in detail the results of key international trials of HT, first and second lines of chemotherapy, targeted therapy, immunotherapy, and immunotherapeutic/ targeted agents for disseminated EC. Biological markers, such as MSI and PD-L1, their correlation with the response rate, and the mechanism of synergy between pembrolizumab and lenvatinib are discussed in detail.
- Open Access
- 9 December 2019
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 19,p. 92-102
Results of using 3-component regimen TEGOXIRI (tegafur, oxaliplatin, irinotecan) ± Leucovorin in patients with advanced colorectal cancer
Результаты применения трехкомпонентного режима TEGOXIRI (тегафур, оксалиплатин, иринотекан) ± Лейковорин у пациентов с распространенным колоректальным раком
- 9 December 2019
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 19,p. 92-102
Open AccessResults of using 3-component regimen TEGOXIRI (tegafur, oxaliplatin, irinotecan) ± Leucovorin in patients with advanced colorectal cancer
Результаты применения трехкомпонентного режима TEGOXIRI (тегафур, оксалиплатин, иринотекан) ± Лейковорин у пациентов с распространенным колоректальным раком
- Open Access
- 3 November 2018
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 8 (3) , 26-35
Impact of topoisomerase IIα overexpression in the primary colon tumor on the prognosis of metastatic colorectal cancer
Background. The evaluation of clinical and morphological characteristics is not sufficient to predict the prognosis of metastatic colorectal cancer (mRCC). Tumor aggressiveness may vary significantly even in patients with similar clinical and morphological disease characteristics. These differences are believed to be associated with molecular tumor characteristics and can be used as additional prognostic factors for patient survival.Objective: to evaluate the effect of topoisomerase IIα overexpression (topoIIα) in primary colon tumor on the mRCC prognosis.Materials and methods. The study cohort included patients with mRCC that have not previously received treatment for disseminated disease. All participants had a morphologically verified diagnosis of colon adenocarcinoma and received first-line chemotherapy with oxaliplatin and capecitabine. We evaluated both short-term and long-term treatment outcomes. We also assessed the expression of topoIIα in primary colon tumors (biopsy/surgical specimens obtained prior to initiation of first-line treatment) using immunohistochemical methods. We aimed to evaluate the association between the level of topoIIα expression and short-term/long-term treatment outcomes. We analyzed the impact of topoIIα expression in the primary tumor on the efficacy of first-line chemotherapy, progression-free survival (PFS) and overall survival (OS) in patients with mRCC.Results. Immunohistochemical evaluation of topoIIα expression in the primary tumor was conducted for 39 patients with mRCC. We found no correlation between topoIIα expression and PFS, i.e. median PFS did not differ significantly between patients with topoIIα-positive and topoIIα-negative tumors (p 0.05). Individuals with low levels of topoIIα expression in the primary tumor and those with topoIIα-negative cancer demonstrated significantly higher OS than patients with topoIIα overexpression (median OS 16.30 ± 2.0 months; 95 % confidence interval 12.32–20.28 vs 7.7 ± 4.98 months; 95 % confidence interval 0.00–17.46; p = 0.007).Conclusion. Overexpression of topoIIα is a factor of poor prognosis associated with poorer OS in patients with mRCC that received first-line chemotherapy with oxaliplatin and capecitabine.
- 3 November 2018
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 8 (3) , 26-35
Open AccessImpact of topoisomerase IIα overexpression in the primary colon tumor on the prognosis of metastatic colorectal cancer
Background. The evaluation of clinical and morphological characteristics is not sufficient to predict the prognosis of metastatic colorectal cancer (mRCC). Tumor aggressiveness may vary significantly even in patients with similar clinical and morphological disease characteristics. These differences are believed to be associated with molecular tumor characteristics and can be used as additional prognostic factors for patient survival.Objective: to evaluate the effect of topoisomerase IIα overexpression (topoIIα) in primary colon tumor on the mRCC prognosis.Materials and methods. The study cohort included patients with mRCC that have not previously received treatment for disseminated disease. All participants had a morphologically verified diagnosis of colon adenocarcinoma and received first-line chemotherapy with oxaliplatin and capecitabine. We evaluated both short-term and long-term treatment outcomes. We also assessed the expression of topoIIα in primary colon tumors (biopsy/surgical specimens obtained prior to initiation of first-line treatment) using immunohistochemical methods. We aimed to evaluate the association between the level of topoIIα expression and short-term/long-term treatment outcomes. We analyzed the impact of topoIIα expression in the primary tumor on the efficacy of first-line chemotherapy, progression-free survival (PFS) and overall survival (OS) in patients with mRCC.Results. Immunohistochemical evaluation of topoIIα expression in the primary tumor was conducted for 39 patients with mRCC. We found no correlation between topoIIα expression and PFS, i.e. median PFS did not differ significantly between patients with topoIIα-positive and topoIIα-negative tumors (p 0.05). Individuals with low levels of topoIIα expression in the primary tumor and those with topoIIα-negative cancer demonstrated significantly higher OS than patients with topoIIα overexpression (median OS 16.30 ± 2.0 months; 95 % confidence interval 12.32–20.28 vs 7.7 ± 4.98 months; 95 % confidence interval 0.00–17.46; p = 0.007).Conclusion. Overexpression of topoIIα is a factor of poor prognosis associated with poorer OS in patients with mRCC that received first-line chemotherapy with oxaliplatin and capecitabine.